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Abstract 
The present review article purposes to introduce the molecular 
mechanisms underlying acute myeloid leukemia (AML). An overview of 
AML was introduced including its classification, therapeutic options and the 
roles of mutations in p53 and WT1 genes. The possibility of molecular 
targeting therapies was also discussed. The efforts of many researchers 
concerning AML were taken into consideration during this review.  
We also pointed to the various roles of WT1 gene as suppressor or oncogene. 
The important relationship between p53 gene and WT1 gene was highlighted 
so that when WT1 gene stabilizes p53, the pathological picture concerning 
p53 if being mutated or not should be reconsidered again. 
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Introduction 
Mutations Associated with Acute Myeloid Leukemia (AML) 
Several studies have recently emphasized the presence of recurring 
mutations in several genes with biologic and prognostic implications to be 
characterized in AML, particularly within the normal karyotype and/or 
intermediate-risk cytogenetic subset. Those genes in which mutations may 
affect disease classification and risk stratification schemes include FLT3, 
NPM, NRAS, MLL, and CEBPA (Ito et al., 2006; Mrozek et al., 2007). 
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Mutations Associated With WT1 
Mutations in the WT1 gene have been included to predispose to AML 
(Gaidzik, Dohner, 2008; Gaidzik et al., 2009; Renneville et al., 2009). The 
expression of WT1 is localized mainly in tissues of the developing 
genitourinary and hematopoietic systems, and mutations in WT1 occur in 
both syndrome-associated and sporadic cases of nephroblastoma (Wilms 
tumor), the most common childhood renal malignancy (Little et al., 2004).  
Other studies also indicated the expression of WT1 in CD34 hematopoietic 
progenitors and its overexpression in a subset of acute leukemias (Vardiman 
et al., 2002). 
The WT1 protein comprises of a proline-glutamine–rich N-terminal 
transcriptional regulatory domain (exons 1-6), in addition to  4 C-terminal 
zinc finger domains (exons 7-10)  which, in turn, facilitate DNA binding 
(Scharnhorst  et al., 2001). Exons 5 and 9 were shown to be under the effect 
of alternative splicing, leading to 4 different splice isoforms. Furthermore, 
posttranslational modifications and alternate start codons can result in 
additional protein products (Phoenix et al., 2010). The WT1 protein may 
have various roles such as a transcriptional activator or a transcriptional 
repressor. The variety of roles of WT1 depends on several factors including 
the level of expression, the specific isoform, and the cellular context (Yang 
et al., 2007). 
Mutations of WT1in relation AML were mainly reported to be in the 
zinc-finger domains, which lead to producing a protein that is expected to be 
unable to bind DNA. Most mutations have been reported to occur in exon 7. 
Taken together, a premature stop codon and a truncated protein lacking the 
C-terminal zinc fingers would be resulted (Paschka et al, 2008; Virappane et 
al., 2008; Renneville et al., 2009).  
It has been reported that missense mutations predominate in exon 9, 
such mutations interrupt DNA binding capacity through affecting amino acid 
residues either directly involved in DNA binding or essential to the structure 
of the zinc-finger motif (Little et al., 2004). 
 
Classification of AML 
According to the French-American-British (FAB) system, the 
subtypes of AML were described as M0 through M7. Another classification 
was adopted by the World Health Organization (WHO) in which AML was 
reclassified into four categories. The four categories are AML with recurrent 
genetic abnormalities, AML with multilineage dysplasia, therapy-related 
AML and myelodysplastic syndromes (Vardiman et al., 2002). 
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Treatment of AML 
There are two approaches to treat AML based on cytarabine and 
anthracyclines. The outcomes associated with AML are still remaining poor, 
especially for those patients who are older or carry higher-risk disease. New 
updates in AML therapy have led to the development and study of novel 
agents that target AML by diverse and varied mechanisms among which are 
targeted therapeutics such as kinase inhibitors and oligonucleotide 
constructs. Other choices include inhibitors of histone deacetylase, which 
cause growth arrest and apoptosis through histone acetylation and resultant 
conformational changes (Amir et al., 2010). 
Other studies discussed that that the majority of patients under age 60 
accomplish a complete remission (CR) with traditional anthracycline and 
cytarabine based induction regimens. But the problem encountered is due to 
poor long-term survival rates approximately 30–40% (Lowenberg et al., 
1999). Furthermore, it has been shown to have poorer prognosis for those 
with high-risk AML, such as those who are older, who had preceding 
myelodysplastic syndromes (MDS) or myeloproliferative disorders (MPD), 
or those with secondary AML from environmental exposures or prior 
chemotherapy. A complete remission is achieved in less than 40% of cases, 
with survival rates of less than 10% (Bao et al., 2005). 
New class of therapies are concerned with developing agents which 
target cell signaling and cycling, as well as those which interrupt DNA repair 
and replication. Some of these therapies are still in early phases of 
development and study, while others have shown promise in preclinical and 
clinical investigation (Amir et al, 2010). 
 
The Effect of WT1 on Apoptosis  
There is a considerable evidence indicating that one of the functions 
of WT1 is regulate apoptosis, but there is a debate arising from conflicting 
reports whether the role of  WT1 is pro- or anti-apoptotic. Thorough revision 
of literature indicates that the apparent contradictions probably reflect cell 
lineage and isoform-specific differences in WT1 function. Furthermore, 
expression of WT1 inhibits programmed cell death in some cell types but 
promotes it in others. It has also been indicated that different WT1 isoforms 
can exert distinct effects as well. A relationship between the mechanisms by 
which WT1 regulates apoptosis and  bcl-2 family members has been 
established and showed to either direct or indirect WT1 target genes, 
including bcl-2 itself, the pro-apoptotic family members Bak and Bax, and 
the anti-apoptotic family member Bfl-1/A1.it has also been shown that the 
specific bcl-2 family members regulated by WT1 expression vary by cell 
type and by isoform. Thus, a complete understanding of the role of WT1 in 
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apoptosis should take into account that both lineage- and isoform-specific 
effects of WT1 at both the cellular and molecular levels (Loeb, 2006). 
 
The Role of P53 in Hematological Cancer 
It has been shown through literature that the inactivation of the wild-
type p53 gene (TP53) attributed by various genetic alterations to be a major 
event in human carcinogenesis. Furthermore, it has been estimated that more 
than 60% of human primary tumors have a mutation in the p53 gene. On the 
other hand, genetic alterations in the p53 gene have low incidence (10–20%). 
However, epidemiological studies of the hematological malignancies have 
indicated that the prognosis of patients with a mutation in the p53 gene is 
worse than those expressing the wild-type p53 protein (Peller  and Rotter, 
2003). 
Several studies reported that p53 mutations as an independent factor 
for short survival, mainly in elderly patients with unfavorable karyotype 
(Nakano et al., 2000; Stirewalt et al., 2001). However, it has been reported 
that in patients with AML previously treated with alkylating agents, the 
incidence of mutations increased to 27% (Christiansen et al., 2001).  It has 
also been found that a high incidence of mutations in AML patients to be 
associated with defective DNA mismatch repair and complex karyotype 
(Zhu et al., 1999). The previous findings have also been confirmed a meta-
analysis of a number of studies which indicated a low incidence of p53 
mutations (5%) on infant acute lymphatic leukemia (ALL) (Krug et al., 
2000).   
Studies on human leukemia-lymphoma cell lines revealed mutations 
on p53 gene (Prokocimer et al., 1998). Another interesting observation 
points to the alterations in the p53 gene It has been recently observed that 
p53 gene alterations often emerge in cell lines although the original tumor 
cells had wild-type p53 (Peller and Rotter, 2003). Furthermore, evidence was 
shown that p53 alteration in a minor clone may confer a survival advantage 
to malignant cells in vitro and presumably also in vivo (Drexler et al., 2000).  
 
TP53 and Apoptosis 
It has been found that p53 has the ability to act as a substrate for jun 
N-terminal kinase (JNK) activity in JNK signaling-induced apoptosis. In this 
process,  JNK can act as either to destabilize p53 through binding, promoting 
ubiquitin-mediated degradation, or to stabilize p53 by phosphorylation, and 
by thus it inhibits its degradation. p53-dependent apoptosis includes parallel 
or sequential activation of various genes leading to cell death response. 
Through this pathway involves, there is an activation of the mitochondrial 
Apaf-1/caspase pathway, death receptor signaling, CD95, and cleavage of 
downstream caspases (Herr and Debatin, 2001).  
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Patients with hematological malignancies are subjecting to various 
therapeutic options among which are cytotoxic agents including DNA 
damaging drugs, antimetabolites, mitotic inhibitors, purine analogues, or 
inhibitors of topoisomerase. All these treatments lead to the induction of 
cellular stress, which, in turn,  elicit apoptosis. p53-induced apoptosis in 
various hematological tumors is often impaired and thus p53-independent 
pathways may take over. As an example, in pediatric acute lymphoblastic 
leukemia, primary leukemic cells and derived cell lines presented 
Fas(CD95)-mediated apoptosis with high levels of Fas expression in p53 
mutant cells but not in p53 wild-type cells (Zhou et al., 1998).  
In AML patients, there are various types of leukemic cells that can be 
detected by their high- or low-uptake of daunorubicin. The high uptake cells 
leads to induction of apoptosis. This intra clonal heterogeneity in drug uptake 
is thought to contribute to relapse in AML patients (Palucka et al., 1999).  
 
WT1 and Leukemia: dual roles, a tumor suppressor or an oncogene? 
There has been a debate in literature if WT1 works as a tumor 
suppressor or as an oncogene. Furthermore, the difficulty in understanding 
the biology of WT1 is attributed to the existence of different splice isoforms, 
which have different functions and are differentially expressed as well as 
WT1’s controversial role in leukaemogenesis. What makes the picture more 
complicated is that although WT1 has been firstly identified in Wilms’ 
tumors due to mutations, about 10%  of the Wilms’ tumors actually have 
mutations in the gene (Haber et al., 1990, 1993; Gessler et al., 1994).  
Accordingly, it is believed that other loci may be involved, e.g., FWT1 
(Rahman et al., 1996). An interesting observation has been found in which 
Wilms’ tumor patients develop leukemia as a second primary tumor (Moss et 
al., 1989; Pritchard., 1994). 
Furthermore, it has been reported that leukaemias are common in 
relatives of children with Wilms’ tumor. It has also been observed that 
WT1is involved during early haematopoiesis as well as its very high 
expression in more undifferentiated progenitor CD34+/CD33- cells (100-fold 
more than in differentiated precursors CD33+) leads to the question on 
whether WT1 is also implicated in leukaemogenesis (Maurer et al., 1997).   
Research trials to introduce the appropriate answer has been shown to 
be contradictory because WT1 has been found to be mutated in sporadic 
leukaemia at a rate of 10%, which is comparable to Wilms’tumors and at a 
rate of 15% in AML patients (King-Underwood et al., 1996). It is worth 
mentioning that most of the mutations identified led to zinc-finger loss and a 
C-terminally truncated WT1 protein would lose its DNA binding ability but 
would retain its protein-protein interaction capacity, having, however, its 
usual function altered. It is also worth mentioning that even heterozygous 
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mutations are sufficient to contribute to leukaemogenesis (King-Underwood 
et al., 1998). This finding is explained depending on the resulting mutation 
so that if the result of the mutation is a truncated protein that can still self-
associate, which, in turn, alters the subnuclear localization of the wild-type 
protein and produce WT1 proteins that act in a dominant negative manner 
(Englert et al., 1995). Taken together, these characteristics give WT1 a tumor 
suppressor function, which leads to leukaemogenesis when lost due to 
mutation during early haematopoiesis. Other studies revealed oncogenic role 
for WT1 based on its overexpression in acute leukaemic cell lines and acute 
leukaemias of myeloid and lymphoid origin (Menssen et al., 1995; Inoue et 
al.., 1997).  
Other researchers found that high expression of WT1 to be correlated 
with less-differentiated phenotypes (Pritchard-Jones and King-Underwood, 
1997). In another study, it was found that overexpression is thought to be 
isoform-dependent as it has been associated with an excess of the exon-5 
containing WT1 variant (Renshaw et al., 1997). 
 
WT1 monitoring in core binding factor AML 
In view of the fact that minimal residual disease may help to establish 
clinical decisions in patients with AML.  Lasa (2009) reported that WT1 
offers the possibility to analyze those cases without currently known 
underlying genetic abnormalities. Lasa tried to compare the value of 
chimeric specific quantitative PCR withWT1 PCR in CBF acute leukemia. 
Accordingly, 445 samples from 96 AML (49 AML1-ETO+ and 47 CBFB-
MYH11+) cases were included in the study. AML1-ETO or CBFB-MYH11 
levels were obtained using the conditions of the BIOMED group and 
compared with the results of WT1 levels using sensitive primers and 
conditions. Simultaneously, normal range expression of WT1 was 
established using RNA obtained from eight healthy donors. WT1 mutations 
were also investigated both at RNA and at the genomic level. The majority 
of CBF samples showed rises in WT1 levels (88.7%) at diagnosis. However, 
18% of AML1- ETO showedWT1 levels below250 copies in contrast with 
5% CBFB-MYH11 cases.WT1 mutation was not detected in any case (70 
diagnostic samples). There was a correlation betweenWT1 levels at 
diagnosis and the CD34 blast population estimated by flow cytometry in 
CBFB-MYH11+ cases. It was also found that no association between WT1 
levels and clinical outcome. A high concordance between chimeric transcript 
analysis and WT1 levels in CR patients was also found. Concordance was 
also high in relapsed patients (78% in AML1-ETO and 98% in CBFB-
MYH11+ cases). BothWT1 and specific chimeric transcript identified and 
rescued false negative results of the other test. It was recommended that 
additional studies are needed to determine whether the rare discrepancies are 
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a reflection of the cooperative nature of WT1 overexpression or a 
consequence of the uneven distribution in the leukemic population.  Lasa 
concluded that WT1 is a powerful MRD tool even in cases with currently 
available molecular targets. 
In a study conducted by Gu (2010), real-time quantitative reverse 
transcriptase polymerase chain reaction method was established for detecting 
the expression levels of WT1 gene and WT1+17AA isoforms in 226 AML 
bone marrow (BM) cells. It was found that WT1 gene was 2–3 logarithms 
expressed more in AML BM cells at initial diagnosis or relapse than in 
normal BM cells (p < 0.001), with predominant WT1+17AA isoforms 
expression (the ratio of WT1+17AA/WT1 more than 0.50). It is worth 
mentioning that the ratio of WT1+17AA/WT1was statistically higher in 
relapsed AMLs than in initially diagnosed (p = 0.01), indicating 
thatWT1+17AA isoforms might participate in AML relapse. 
Gray (2012) conducted a study and showed that WT1 levels may be a 
useful predictor of leukemia free survival (LFS) following treatment of acute 
myeloid leukemia (AML). A retrospective study in which levels of WT1 
expression from patients with de novo AML were measured from bone 
marrow and peripheral blood at diagnosis, post-induction, postconsolidation 
and relapse was reported. It was demonstrated that higher levels of WT1 in 
peripheral blood at diagnosis are associated with poorer LFS independent of 
age and cytogenetic risk-group (n = 85, p = 0.028). When measured at post-
consolidation, the presence of detectable WT1 was shown to be associated 
with poorer LFS in univariate analysis of both peripheral blood (p = 0.024) 
and bone marrow (p = 0.019). In a multivariate analysis including age and 
cytogenetic risk, the association remained significant for bone marrow (p = 
0.016) with a trend observed for peripheral blood (p = 0.06).  
In his study, Ishikawa (2011) showed that overexpression of the 
Wilms’ tumor gene 1 (WT1) to be observed in most leukemia cells. In 
addition to four major isoforms of WT1, an N-terminally truncated isoforms 
(sWT1) has been identified. The research group quantified the transcript 
levels of sWT1 and full-length WT1 (fWT1) in 237 patients with acute 
myeloid leukemia (AML). sWT1expression was observed in 45 of 237 
(19.0%) AML patients, particularly in acute promyelocytic leukemia 
(59.3%). Although sWT1 expression was not associated with other genetic 
mutations and prognosis, fWT1 expression level in sWT1-expressing AML 
was significantly higher than that in un-expressing AML. The previous 
findings led to propose a possible cooperation of sWT1 and fWT1 in the 
pathophysiology of AML.  
Zhao (2010) conducted a study taking into consideration that the p53 
tumor suppressor can limit proliferation in response to cellular stress through 
several mechanisms. Here, the research team test if the recently described 
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ability of p53 to limit stem cell self-renewal suppresses tumorigenesis in 
acute myeloid leukemia (AML)which is an aggressive cancer in which p53 
mutations have been reported to associate with drug resistance and adverse 
outcome. The research team adopted an approach combined mosaic mouse 
models, Cre-lox technology, and in vivo RNAi to disable p53 and 
simultaneously activate endogenous Kras G12D a common AML lesion that 
promotes proliferation but not self-renewal. Study data  showed that p53 
inactivation strongly cooperates with oncogenic Kras G12D to induce 
aggressive AML, while both lesions on their own induce T-cell malignancies 
with long latency. This synergy is thought to be mediated by a pivotal role of 
p53 in limiting aberrant self-renewal of myeloid progenitor cells, such that 
loss of p53 counters the deleterious effects of oncogenic Kras on these cells 
and enables them to self-renew indefinitely. As a result, myeloid progenitor 
cells expressing oncogenic Kras and lacking p53 become leukemia-initiating 
cells, resembling cancer stem cells capable of maintaining AML in vivo. 
Taken together, these findings establish an efficient new strategy for 
interrogating oncogene cooperation, and provide strong evidence that the 
ability of p53 to limit aberrant self renewal contributes to its tumor 
suppressor activity. 
Paydas (1995) investigated the expression of p53 protein by 
immunohistochemistry in 58 patients with leukemia. The study showed 
positive expression of p53 in 7 of 24 cases with acute myeloid leukemia 
(AML), 3 of 15 cases with chronic lymphocytic leukemia (CLL), one of 11 
cases with chronic myeloid leukemia (CML) and 4 of 8 cases with acute 
lymphoid leukemia (ALL). Further analysis revealed that of patients having 
p53 expression, one case with AML had refractory anemia with excess 
blasts-transformation (RAEB/t), one case with CLL had Richter's syndrome 
and another one with CML was in accelerated phase. Taken together, 26% of 
leukemia cases had p53 protein expression. Finally, it was concluded that 
p53 protein abnormalities may have an important role in leukomogenesis and 
in the development of more malignant clones in chronic leukemias. 
Cell cycle control is a crucial event in normal hematopoiesis, and 
abnormalities of regulatory cell cycle genes have been found  by a study 
conducted by Zolota (2007) to contribute to the development of many 
hematologic malignancies. The present study investigates the 
immunohistochemical expression of seven essential cell cycle proteins (p21, 
p27, p14, p16, p53, mdm2, and cyclin E) in paraffin-embedded sections from 
42 bone marrow biopsies obtained from an equal number of patients with 
newly diagnosed acute myeloid leukemia (AML). This study revealed (i) a 
high frequency of p53+/mdm2-/p21-phenotype, which is probably a result of 
p53 gene mutation and/or inhibition of mdm2 action by p14(ARF); (ii) 
expression of p27+/cyclinE-phenotype in most cases, suggesting that p27 
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may act as a potent cyclin-dependent kinase inhibitor; (iii) expression of p16 
only in very few cases; and (iv) no relationship between the expression of 
any of the above proteins and survival as well as histologic subtype. 
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